- Report
- March 2024
- 184 Pages
Global
From €3277EUR$3,374USD£2,827GBP
€3641EUR$3,749USD£3,141GBP
- Report
- April 2024
- 175 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- January 2024
- 200 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Clinical Trials
- April 2024
- 250 Pages
Global
From €2914EUR$3,000USD£2,514GBP
- Clinical Trials
- April 2024
- 50 Pages
Global
€1457EUR$1,500USD£1,257GBP
- Report
- February 2024
- 150 Pages
Global
From €4128EUR$4,250USD£3,561GBP
- Report
- March 2024
- 200 Pages
Global
From €4031EUR$4,150USD£3,477GBP
- Report
- April 2022
- 191 Pages
Global
From €3093EUR$3,185USD£2,669GBP
€4419EUR$4,550USD£3,812GBP
- Report
- April 2023
- 117 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- April 2023
- 115 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Report
- July 2022
- 100 Pages
Global
From €2671EUR$2,750USD£2,304GBP
- Report
- January 2022
- 419 Pages
Global
From €9227EUR$9,500USD£7,960GBP
- Report
- November 2021
- 101 Pages
Global
From €4371EUR$4,500USD£3,770GBP
- Report
- August 2022
- 120 Pages
Global
From €4614EUR$4,750USD£3,980GBP
- Drug Pipelines
- February 2018
- 27 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Drug Pipelines
- February 2018
- 17 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Report
- February 2018
- 17 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Report
- February 2018
- 17 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Report
- July 2018
- 30 Pages
Global
From €9713EUR$10,000USD£8,379GBP
- Report
- July 2018
- 17 Pages
Global
From €9713EUR$10,000USD£8,379GBP
Formoterol is a long-acting beta-2 agonist (LABA) used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is a bronchodilator, meaning it relaxes the muscles in the airways, allowing more air to flow in and out of the lungs. Formoterol is typically used in combination with an inhaled corticosteroid (ICS) to provide long-term control of symptoms. It is also used as a rescue medication to provide quick relief from acute symptoms.
Formoterol is available in both metered-dose inhalers (MDIs) and dry powder inhalers (DPIs). It is also available in combination with other drugs, such as budesonide and mometasone. Formoterol is generally well-tolerated, with few side effects.
Formoterol is one of the most widely used drugs in the respiratory market. It is used to treat a variety of conditions, including asthma, COPD, and bronchospasm. It is also used as a rescue medication for acute symptoms.
Some companies in the Formoterol market include GlaxoSmithKline, Merck, Novartis, and Boehringer Ingelheim. Show Less Read more
